Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

为了进一步提高KRAS G12C突变患者的治疗效果，研究团队设计了一项临床试验。他们尝试将靶向药索托拉西布与传统化疗（卡铂和培美曲塞）相结合，用于治疗晚期非鳞状非小细胞肺癌患者。

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

A study led by USC Assistant Professor of Computer Science Ruishan Liu has uncovered how specific genetic mutations influence ...

A groundbreaking study has uncovered how specific genetic mutations influence cancer treatment outcomes -- insights that could help doctors tailor treatments more effectively. The largest study of its ...

Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...

AI creates anti-cancer molecules for proteins that previously could not be targeted pharmacologically by leveraging quantum ...

Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...

The research, led by CCU Department of Physiology Chair Professor Tsai Shaw-jenq and NCKU College of Medicine Dean Shan ...